Recurrent Malignant Solid Neoplasm Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0082715 (Recurrent Malignant Solid Neoplasm)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04171219Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersTreatment
NCT03428802Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityTreatment
NCT03229278Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaTreatment